nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

05.10.2018 | Original Article

Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients

verfasst von: Adrienne Müller Herde, Roger Schibli, Markus Weber, Simon M. Ametamey

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the present study was to determine the expression levels of mGluR5 in different mouse strains after induction of neuroinflammation by lipopolysaccharide (LPS) challenge and in the brains of patients with Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) post mortem to investigate mGluR5 expression in human neurodegenerative diseases.

Methods

C57BL/6 and CD1 mice were injected intraperitoneally with either 10 mg/kg LPS or saline. mGluR5 and TSPO mRNA levels were measured after 1 and 5 days by qPCR, and mGluR5 protein levels were determined by PET imaging with the mGluR5-specific radiotracer [¹⁸F]PSS232. mGluR5 expression was evaluated in the post-mortem brain slices from AD and ALS patients using in vitro autoradiography.

Results

mGluR5 and TSPO mRNA levels were increased in brains of C57BL/6 and CD1 mice 1 day after LPS treatment and remained significantly increased after 5 days in C57BL/6 mice but not in CD1 mice. Brain PET imaging with [¹⁸F]PSS232 confirmed increased mGluR5 levels in the brains of both mouse strains 1 day after LPS treatment. After 5 days, mGluR5 levels in CD1 mice declined to the levels in vehicle-treated mice but remained high in C57BL/6 mice. Autoradiograms revealed a severalfold higher binding of [¹⁸F]PSS232 in post-mortem brain slices from AD and ALS patients compared with the binding in control brains.

Conclusion

LPS-induced neuroinflammation increased mGluR5 levels in mouse brain and is dependent on the mouse strain and time after LPS treatment. mGluR5 levels were also increased in human AD and ALS brains in vitro. PET imaging of mGluR5 levels could potentially be used to diagnose and monitor therapy outcomes in patients with AD and ALS.

Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129:154–69. https://doi.org/10.1111/j.1365-2567.2009.03225.x.CrossRefPubMedPubMedCentral

Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14:457–87. https://doi.org/10.1111/j.1582-4934.2010.01010.x.CrossRefPubMedPubMedCentral

Tohidpour A, Morgun AV, Boitsova EB, Malinovskaya NA, Martynova GP, Khilazheva ED, et al. Neuroinflammation and infection: molecular mechanisms associated with dysfunction of neurovascular unit. Front Cell Infect Microbiol. 2017;7:276. https://doi.org/10.3389/fcimb.2017.00276.CrossRefPubMedPubMedCentral

Nazem A, Sankowski R, Bacher M, Al-Abed Y. Rodent models of neuroinflammation for Alzheimer’s disease. J Neuroinflammation. 2015;12:74. https://doi.org/10.1186/s12974-015-0291-y.CrossRefPubMedPubMedCentral

Catorce MN, Gevorkian G. LPS-induced murine neuroinflammation model: main features and suitability for pre-clinical assessment of nutraceuticals. Curr Neuropharmacol. 2016;14:155–64.CrossRefPubMedPubMedCentral

Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal. 2012;2012:756357. https://doi.org/10.1100/2012/756357.CrossRefPubMedPubMedCentral

Nadeau S, Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience. 1999;93:1449–64.CrossRefPubMed

Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453–62. https://doi.org/10.1002/glia.20467.CrossRefPubMedPubMedCentral

Ifuku M, Katafuchi T, Mawatari S, Noda M, Miake K, Sugiyama M, et al. Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. J Neuroinflammation. 2012;9:197. https://doi.org/10.1186/1742-2094-9-197.CrossRefPubMedPubMedCentral

10.

Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis. 2003;14:133–45.CrossRefPubMed

11.

Crawshaw AA, Robertson NP. The role of TSPO PET in assessing neuroinflammation. J Neurol. 2017;264:1825–7. https://doi.org/10.1007/s00415-017-8565-1.CrossRefPubMedPubMedCentral

12.

Drouin-Ouellet J, Brownell AL, Saint-Pierre M, Fasano C, Emond V, Trudeau LE, et al. Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia. 2011;59:188–99. https://doi.org/10.1002/glia.21086.CrossRefPubMed

13.

Piers TM, Kim DH, Kim BC, Regan P, Whitcomb DJ, Cho K. Translational concepts of mGluR5 in synaptic diseases of the brain. Front Pharmacol. 2012;3:199. https://doi.org/10.3389/fphar.2012.00199.CrossRefPubMedPubMedCentral

14.

Byrnes KR, Loane DJ, Stoica BA, Zhang J, Faden AI. Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury. J Neuroinflammation. 2012;9:43. https://doi.org/10.1186/1742-2094-9-43.CrossRefPubMedPubMedCentral

15.

Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci. 2000;20:7871–9.CrossRefPubMedPubMedCentral

16.

Jong YJ, Kumar V, O’Malley KL. Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signalling cascades distinct from cell surface counterparts. J Biol Chem. 2009;284:35827–38. https://doi.org/10.1074/jbc.M109.046276.CrossRefPubMedPubMedCentral

17.

Abushik PA, Niittykoski M, Giniatullina R, Shakirzyanova A, Bart G, Fayuk D, et al. The role of NMDA and mGluR5 receptors in calcium mobilization and neurotoxicity of homocysteine in trigeminal and cortical neurons and glial cells. J Neurochem. 2014;129:264–74. https://doi.org/10.1111/jnc.12615.CrossRefPubMed

18.

Luyt K, Varadi A, Durant CF, Molnar E. Oligodendroglial metabotropic glutamate receptors are developmentally regulated and involved in the prevention of apoptosis. J Neurochem. 2006;99:641–56. https://doi.org/10.1111/j.1471-4159.2006.04103.x.CrossRefPubMed

19.

Milicevic Sephton S, Müller Herde A, Mu L, Keller C, Rudisuhli S, Auberson Y, et al. Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). Eur J Nucl Med Mol Imaging. 2015;42:128–37. https://doi.org/10.1007/s00259-014-2883-7.CrossRef

20.

Müller Herde A, Keller C, Milicevic Sephton S, Mu L, Schibli R, Ametamey SM, et al. Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity. J Neurochem. 2015;133:330–42. https://doi.org/10.1111/jnc.13001.CrossRefPubMed

21.

Arsenault D, Coulombe K, Zhu A, Gong C, Kil KE, Choi JK, et al. Loss of metabotropic glutamate receptor 5 function on peripheral benzodiazepine receptor in mice prenatally exposed to LPS. PLoS One. 2015;10:e0142093. https://doi.org/10.1371/journal.pone.0142093.CrossRefPubMedPubMedCentral

22.

Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med. 2007;48:247–52.PubMed

23.

Ferraguti F, Corti C, Valerio E, Mion S, Xuereb J. Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5. Exp Brain Res. 2001;137:1–11.CrossRefPubMed

24.

D’Ascenzo M, Fellin T, Terunuma M, Revilla-Sanchez R, Meaney DF, Auberson YP, et al. mGluR5 stimulates gliotransmission in the nucleus accumbens. Proc Natl Acad Sci U S A. 2007;104:1995–2000. https://doi.org/10.1073/pnas.0609408104.CrossRefPubMedPubMedCentral

25.

Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995;34:1–26.CrossRefPubMed

26.

Endoh T. Characterization of modulatory effects of postsynaptic metabotropic glutamate receptors on calcium currents in rat nucleus tractus solitarius. Brain Res. 2004;1024:212–24. https://doi.org/10.1016/j.brainres.2004.07.074.CrossRefPubMed

27.

Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci. 2001;21:5925–34.CrossRefPubMedPubMedCentral

28.

Kumar A, Dhull DK, Mishra PS. Therapeutic potential of mGluR5 targeting in Alzheimer’s disease. Front Neurosci. 2015;9:215. https://doi.org/10.3389/fnins.2015.00215.CrossRefPubMedPubMedCentral

29.

De Maio A, Mooney ML, Matesic LE, Paidas CN, Reeves RH. Genetic component in the inflammatory response induced by bacterial lipopolysaccharide. Shock. 1998;10:319–23.CrossRefPubMed

30.

Hopkins W, Gendron-Fitzpatrick A, McCarthy DO, Haine JE, Uehling DT. Lipopolysaccharide-responder and nonresponder C3H mouse strains are equally susceptible to an induced Escherichia coli urinary tract infection. Infect Immun. 1996;64:1369–72.PubMedPubMedCentral

31.

Yang IV, Rutledge HR, Yang J, Warg LA, Sevilla SD, Schwartz DA. A locus on chromosome 9 is associated with differential response of 129S1/SvImJ and FVB/NJ strains of mice to systemic LPS. Mamm Genome. 2011;22:518–29. https://doi.org/10.1007/s00335-011-9340-8.CrossRefPubMedPubMedCentral

32.

Lopes PC. LPS and neuroinflammation: a matter of timing. Inflammopharmacology. 2016;24:291–3. https://doi.org/10.1007/s10787-016-0283-2.CrossRefPubMed

33.

Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–8.CrossRefPubMed

34.

Brownell AL, Kuruppu D, Kil KE, Jokivarsi K, Poutiainen P, Zhu A, et al. PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene. J Neuroinflammation. 2015;12:217. https://doi.org/10.1186/s12974-015-0439-9.CrossRefPubMedPubMedCentral

35.

Vermeiren C, Hemptinne I, Vanhoutte N, Tilleux S, Maloteaux JM, Hermans E. Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. J Neurochem. 2006;96:719–31. https://doi.org/10.1111/j.1471-4159.2005.03577.x.CrossRefPubMed

36.

Fang XT, Eriksson J, Antoni G, Yngve U, Cato L, Lannfelt L, et al. Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [(11)C]ABP688 PET imaging and ex vivo immunoblotting. Neuropharmacology. 2017;113:293–300. https://doi.org/10.1016/j.neuropharm.2016.10.009.CrossRefPubMed

37.

Lee M, Lee HJ, Park IS, Park JA, Kwon YJ, Ryu YH, et al. Abeta pathology downregulates brain mGluR5 density in a mouse model of Alzheimer. Neuropharmacology. 2018;133:512–7. https://doi.org/10.1016/j.neuropharm.2018.02.003.CrossRefPubMed

38.

Lee HG, Zhu X, O’Neill MJ, Webber K, Casadesus G, Marlatt M, et al. The role of metabotropic glutamate receptors in Alzheimer’s disease. Acta Neurobiol Exp (Wars). 2004;64:89–98.

39.

Byrnes KR, Stoica B, Loane DJ, Riccio A, Davis MI, Faden AI. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia. 2009;57:550–60. https://doi.org/10.1002/glia.20783.CrossRefPubMedPubMedCentral

40.

Loane DJ, Stoica BA, Pajoohesh-Ganji A, Byrnes KR, Faden AI. Activation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase. J Biol Chem. 2009;284:15629–39. https://doi.org/10.1074/jbc.M806139200.CrossRefPubMedPubMedCentral

41.

Caraci F, Nicoletti F, Copani A. Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer’s disease. Curr Opin Pharmacol. 2018;38:1–7. https://doi.org/10.1016/j.coph.2017.12.001.CrossRefPubMed

42.

Haas LT, Kostylev MA, Strittmatter SM. Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). J Biol Chem. 2014;289:28460–77. https://doi.org/10.1074/jbc.M114.584342.CrossRefPubMedPubMedCentral

43.

Hamilton A, Esseltine JL, DeVries RA, Cregan SP, Ferguson SS. Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer’s disease. Mol Brain. 2014;7:40. https://doi.org/10.1186/1756-6606-7-40.CrossRefPubMedPubMedCentral

44.

Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SS. Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model. Cell Rep. 2016;15:1859–65. https://doi.org/10.1016/j.celrep.2016.04.077.CrossRefPubMed

45.

Haas LT, Salazar SV, Smith LM, Zhao HR, Cox TO, Herber CS, et al. Silent allosteric modulation of mGluR5 maintains glutamate signalling while rescuing Alzheimer’s mouse phenotypes. Cell Rep. 2017;20:76–88. https://doi.org/10.1016/j.celrep.2017.06.023.CrossRefPubMedPubMedCentral

46.

Warnock G, Sommerauer M, Mu L, Pla Gonzalez G, Geistlich S, Treyer V, et al. A first-in-man PET study of [(18)F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5. Eur J Nucl Med Mol Imaging. 2018;45:1041–51. https://doi.org/10.1007/s00259-017-3879-x.CrossRefPubMed

Titel: Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients
verfasst von: Adrienne Müller Herde
Roger Schibli
Markus Weber
Simon M. Ametamey
Publikationsdatum: 05.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4179-9

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (Eds.) Bone Metastases from Prostate Cancer: Biology, Diagnosis and Management

A new frontier for amyloid PET imaging: multiple sclerosis

Prognostic analysis of interim 18F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy

Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?

Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer

Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease